Background: Approximately, 5-7 million people are infected with T. cruzi in the world, and approximately 10,000 people per year die of complications linked to this disease.

Methods: This work describes the construction of a new family of hidrazonoyl substituted derivatives, structurally designed exploring the molecular hybridization between megazol and nitrofurazone.

Results and Discussion: The compounds were evaluated for their in vitro activity against bloodstream trypomastigotes of Trypanosoma cruzi, etiological agent of Chagas disease, and for their potential toxicity to mammalian cells.

Conclusion: Among these hydrazonoyl derivatives, we identified the derivative (4) that showed trypanocidal activity (IC50/24 h = 15.0 µM) similar to Bz, the standard drug, and low toxicity to mammalian cells, reaching an SI value of 18.7.

背景：世界上大约有5-7百万人感染克氏锥虫，每年约有10,000人死于与这种疾病有关的并发症。

方法：这项工作描述了新的Hidrazonoyl取代衍生物家族的结构，在结构上设计了探索兆唑和呋喃西林之间的分子杂交的方法。

结果与讨论：评估了这些化合物对锥虫锥虫血流锥虫的体外活性，查加斯锥虫病的病原体及其对哺乳动物细胞的潜在毒性。

结论：在这些酰基衍生物中，我们鉴定了具有与标准药物Bz相似的锥虫杀虫活性（IC50 / 24 h = 15.0 µM）的衍生物（4），对哺乳动物细胞的毒性低，SI值为18.7。